Harrow, Inc. (NASDAQ:HROW) Shares Sold by Millennium Management LLC

Millennium Management LLC trimmed its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 60.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,262 shares of the company's stock after selling 101,671 shares during the period. Millennium Management LLC owned 0.19% of Harrow worth $2,257,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of HROW. Braidwell LP boosted its holdings in Harrow by 106.3% in the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after buying an additional 467,401 shares during the last quarter. Neuberger Berman Group LLC lifted its position in shares of Harrow by 128.0% in the fourth quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company's stock valued at $6,728,000 after acquiring an additional 112,588 shares in the last quarter. Trexquant Investment LP lifted its position in shares of Harrow by 1,806.8% in the fourth quarter. Trexquant Investment LP now owns 94,500 shares of the company's stock valued at $3,170,000 after acquiring an additional 89,544 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Harrow by 100.9% in the fourth quarter. Deutsche Bank AG now owns 108,064 shares of the company's stock worth $3,626,000 after acquiring an additional 54,273 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Harrow by 10,500.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 42,400 shares of the company's stock worth $1,423,000 after acquiring an additional 42,000 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Trading Down 2.1%

Shares of HROW stock traded down $0.64 on Tuesday, hitting $29.34. 740,390 shares of the stock traded hands, compared to its average volume of 497,909. The firm's 50-day moving average price is $25.22 and its two-hundred day moving average price is $30.24. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock has a market capitalization of $1.08 billion, a PE ratio of -31.21 and a beta of 0.41. Harrow, Inc. has a twelve month low of $16.71 and a twelve month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The firm had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. As a group, analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on HROW. HC Wainwright increased their price objective on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th. B. Riley cut their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.